10 flakonluk paket6 stokta%25 tasarrufRetatrutide 30 mg
Üçlü agonist GLP-1 / GIP / glukagon araştırma peptidi
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Yalnızca araştırma kullanımı. Bu bileşik yalnızca in vitro araştırma ve laboratuvar amaçlı satılır; insan tüketimine veya terapötik kullanıma yönelik değildir. Satın alarak nitelikli bir araştırmacı olduğunuzu ve tam sorumluluk reddimizi kabul ettiğinizi onaylarsınız.
Yalnızca 6 paket kaldı
Metabolik araştırma uygulamalarında GLP-1, GIP ve glukagon sinyal yolları üzerindeki birleşik etkileri için incelenen üçlü reseptör agonist araştırma peptidi.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mekanizma
GLP-1, GIP ve glukagon reseptörlerinin eşzamanlı agonizmi için incelenir. Araştırma, çalışma popülasyonlarında metabolik hız, tokluk ve enerji harcaması belirteçleriyle ilişkilendirilir.
≥%99 saflık spesifikasyonuna göre HPLC doğrulaması. Akredite üçüncü taraf laboratuvarlarca bağımsız olarak test edilmiştir.
Retatrutide — sıkça sorulan sorular
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Retatrutide ile ilgili kılavuzlar
Araştırmacılar ayrıca inceler
10 flakonluk paket%22 tasarrufMOTS-c
Liyofilize toz10 mg · 2 strengths
Mitokondri kaynaklı metabolik peptit
2 sette
10 flakonluk paket%17 tasarruf5-Amino-1MQ
Liyofilize toz50 mg · 3 strengths
NNMT inhibitörü araştırma bileşiği
10 flakonluk paket%15 tasarrufL-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitokondriyal yağ asidi taşıyıcısı
1 sette